Wells Fargo
SRNE

Wells Fargo’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

Wells Fargo’s Portfolio SRNE Stock Details SRNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-50,000
Closed -$17K – 7268
2020
Q3 		$17K Buy
+50,000
New +$458K ﹤0.01% 5796

Other funds holding SRNE

PP
Paloma Partners Greenwich, Connecticut $510M AUM 286.05% 1-Year Est. Return
OCM
Oaktree Capital Management Los Angeles, California $6.56B AUM 42.97% 1-Year Est. Return
OFA
Oaktree Fund Advisors Los Angles, California $56.9M AUM 80.32% 1-Year Est. Return
CGA
Crescent Grove Advisors Lake Forest, Illinois $1.04B AUM 17.78% 1-Year Est. Return
LCM
Lattice Capital Management Kirkland, Washington $56.9M AUM 49.15% 1-Year Est. Return
STB
S&T Bank Indiana, Pennsylvania $268M AUM 39.92% 1-Year Est. Return
GA
GoalVest Advisory New York $539M AUM 27.49% 1-Year Est. Return
HFRG
Houlihan Financial Resource Group Ashburn, Virginia $257M AUM 14.19% 1-Year Est. Return
VFA
Valeo Financial Advisors Carmel, Indiana $4.74B AUM 27.69% 1-Year Est. Return
GBWM
Granite Bay Wealth Management Portsmouth, New Hampshire $470M AUM 15.4% 1-Year Est. Return

Wells Fargo's SRNE Position: Q1 2023 in Review

Wells Fargo sold out of Sorrento Therapeutics, Inc. (SRNE) in Q1 2023, closing a stake of 1,039,799 shares — an estimated $921K sold.

Wells Fargo first reported a position in SRNE in Q4 2013 and held it in 36 quarters. The position peaked at $8.55M in Q3 2020. 34 funds tracked by Wall St. Rank hold SRNE as of Q1 2023.

  • Wells Fargo reported no remaining Sorrento Therapeutics, Inc. position as of Q1 2023 after selling out during the quarter.
  • Wells Fargo sold 1,039,799 Sorrento Therapeutics, Inc. shares in Q1 2023, an estimated $921K.
  • Wells Fargo first reported a position in Sorrento Therapeutics, Inc. in Q4 2013 and held it in 36 quarters.
  • Wells Fargo's Sorrento Therapeutics, Inc. position peaked at $8.55M in Q3 2020.
  • 34 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q1 2023.

Based on Wells Fargo's 13F filing for Q1 2023, filed 12 May 2023.